Importantly, anti-PD-1 treatment (Nivolumab) was found to be especially effective in relapsed/refractory cHL, showing the significant role of the PD-1/PD-L1 pathway in this malignancy. This evidence concerns the gene CD274 and classic Hodgkin lymphoma.